Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Citigroup

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) to a hold rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

A number of other brokerages have also issued reports on REGN. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Evercore ISI decreased their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 3.3 %

Shares of REGN opened at $756.81 on Wednesday. The firm has a market capitalization of $83.17 billion, a P/E ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals has a 12-month low of $753.69 and a 12-month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average price of $985.21 and a 200-day moving average price of $1,032.97.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Brown Lisle Cummings Inc. raised its stake in shares of Regeneron Pharmaceuticals by 18.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 10 shares during the period. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Adirondack Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the period. UMB Bank n.a. raised its stake in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 10 shares during the period. Finally, Western Financial Corp CA raised its stake in shares of Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,912,000 after buying an additional 12 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.